TipRanks (Fri, 14-Aug 9:00 AM ET)
Talphera falls despite narrower Q2 loss, NEPHRO trial progress
Seeking Alpha News (Thu, 13-Aug 11:51 AM ET)
TipRanks (Thu, 13-Aug 6:30 AM ET)
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
PRNewswire (Wed, 12-Aug 4:05 PM ET)
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
PRNewswire (Wed, 5-Aug 4:05 PM ET)
Talphera (TLPH) Jumps 36.61% After $5 Million CorMedix Investment—Phase 3 Study in Focus
Market Chameleon (Mon, 8-Sep 7:00 AM ET)
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
Talphera trades on the NASDAQ stock market under the symbol TLPH.
As of August 18, 2026, TLPH stock price climbed to $1.23 with 74,390 million shares trading.
TLPH has a beta of 1.20, meaning it tends to be more sensitive to market movements. TLPH has a correlation of 0.03 to the broad based SPY ETF.
TLPH has a market cap of $63.84 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that TLPH belongs to (by Net Assets): VXF, VTI.
TLPH has outperformed the market in the last year with a return of +189.2%, while the SPY ETF gained +20.6%. In the last 3 month period, TLPH beat the market returning +45.0%, while SPY returned +4.2%. However, in the most recent 2 weeks TLPH has underperformed the stock market by returning -7.5%, while SPY returned +1.4%.
TLPH support price is $1.15 and resistance is $1.26 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLPH shares will trade within this expected range on the day.